Skip to content
StockMarketAgent
Direct answer
Stryker is a high-quality mature compounder with a durable moat derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through. Fair value range: low $225, high $370, with mid-point at $297.
Stock analysis

SYK SYK fair value $225–$370

SYK
By StockMarketAgent.AI team· supervised by
Analyzed: 2026-05-12Next update: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Last price
$294.45
▲ +2.93 (+1.00%)
Fair value
$297
$225–$370
Rating
Hold
confidence 88/100
Upside
+1.0%
upside to fair value
Margin of Safety
$252.77
MoS level · 15%
Market Cap
$112.8B
P/E fwd 17.6

§1 Executive summary

  • Stryker benefits from high switching costs and Mako ecosystem lock-in.
  • Fair value mid-point of $297.38 implies only 1% upside, prompting a Hold.
  • Trades at a massive premium to peers (PEG 2.51), posing severe multiple contraction risk if growth slows.
  • Watch Mako placement volumes and 20.5% operating margin stability.
Fair value
$297
Margin of safety
+1.0%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$294.45Price
Low $225.47
Mid $297.38
High $370.47

Stryker is a high-quality mature compounder with a durable moatMoatA durable structural advantage that protects long-term returns on capital from competition. Sources include network effects, switching costs, intangible assets, cost advantages, and efficient scale. derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through.

  • High switching costs in hospital
    High switching costs in hospital ecosystems
  • Scale economies in MedSurg and
    Scale economies in MedSurg and Orthopaedics
  • Cycle upside
    Accelerating hospital capital expenditures and aging demographics driving elective procedure volumes.

§2 Bear case

A sustained hospital CapExCapital expendituresCash spent on acquiring or upgrading property, plant, and equipment. Splits into maintenance capex (sustaining current capacity) and growth capex (expanding capacity). freeze slows Mako placements, while aggressive GPO negotiations compress implant ASPs, pushing operating margins below 19% and compressing the multiple.

Ways this thesis can break

Multiple Contraction to Peer Median

· Medium

SYK's PEG of 2.51 compresses to the med-tech peer median of 1.56 as Mako-driven growth normalizes.

FV impact
-25%
Trigger
12-24 Months

Orthopaedic Pricing Collapse

· Low

Hospital GPOs successfully leverage increased competition to drive down orthopaedic implant pricing.

FV impact
-15%
Trigger
24-36 Months

Robotics CapEx Freeze

· Medium

Macroeconomic pressures severely constrain hospital capital expenditure budgets, halting Mako placements.

FV impact
-20%
Trigger
6-18 Months
Early-warning signals to monitor
MetricCurrentTrigger threshold
Two consecutive quarters of operating margin falling below 19%.MonitorDeterioration versus the report thesis
Multi-quarter deceleration in Mako placement volumes.MonitorDeterioration versus the report thesis
Explicit pushback on orthopedic implant ASPs from major GPOs.MonitorDeterioration versus the report thesis
Multiple contraction closer to the peer PEG ratio.MonitorDeterioration versus the report thesis
Deceleration in MedSurg equipment cross-selling.MonitorDeterioration versus the report thesis

§3 Financial history

Income statement — last six periods
Line itemT−0T−1T−2T−3CAGR
Period2022-12-312023-12-312024-12-312025-12-31Trend
Revenue$18.45B$20.50B$22.60B$25.12B+10.8%
Gross profit$11.58B$13.06B$14.44B$16.07B+11.5%
Operating income$3.11B$3.92B$4.67B$5.06B+17.6%
Net income$2.36B$3.17B$2.99B$3.25B+11.2%
EPS (diluted)$6.17$8.25$7.76$8.40+10.8%
EBITDA$4.11B$5.06B$4.95B$6.31B+15.4%
R&D$1.45B$1.39B$1.47B$1.62B+3.7%
SG&A$6.39B$7.11B$7.69B$8.65B+10.6%

Quality scores

OCF / Net income
1.55×
>1 indicates high earnings quality
Accounting quality gate
Fail
Sector-adjusted gate
ROIC
10.6%
Return on invested capital
§3

Numbers analysis

Cash flow

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Capital allocation

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Individual subscribers — §4 onwards11 more sections

Read the full analysis — 11 more sections.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Full report for every covered ticker
24 months of rating archive
Watchlist briefings + rating-change alerts
PDF + DOCX export in any language
Start free trial
Cancel anytime.
FAQ

SYK — frequently asked questions

  1. Based on our latest analysis, SYK trades close to fair value. The current price is $294 versus a composite fair-value midpoint of $297 (range $225–$370), which implies roughly 1.0% upside to the midpoint.
Related coverage

Names readers of SYK also follow

Same archetype: mature-compounder